UBS Group
DYN icon

UBS Group’s Dyne Therapeutics DYN Stock Holding History

UBS Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.85M Buy
443,284
+62,723
+16% +$1.17M ﹤0.01% 3468
2026
Q1 		$6.9M Sell
380,561
-417
-0.1% -$7.19K ﹤0.01% 3737
2025
Q4 		$7.45M Buy
380,978
+31,590
+9% +$598K ﹤0.01% 3607
2025
Q3 		$4.42M Buy
349,388
+227,596
+187% +$2.6M ﹤0.01% 4159
2025
Q2 		$1.16M Sell
121,792
-235,962
-66% -$2.6M ﹤0.01% 5314
2025
Q1 		$3.74M Sell
357,754
-182,358
-34% -$2.61M ﹤0.01% 4075
2024
Q4 		$12.7M Sell
540,112
-85,607
-14% -$2.53M ﹤0.01% 2798
2024
Q3 		$22.5M Buy
625,719
+381,790
+157% +$15.2M ﹤0.01% 1727
2024
Q2 		$8.61M Buy
243,929
+10,602
+5% +$308K ﹤0.01% 2344
2024
Q1 		$6.62M Buy
233,327
+109,277
+88% +$2.47M ﹤0.01% 2661
2023
Q4 		$1.65M Buy
124,050
+69,892
+129% +$683K ﹤0.01% 4024
2023
Q3 		$485K Buy
54,158
+31,589
+140% +$340K ﹤0.01% 4672
2023
Q2 		$254K Buy
22,569
+21,120
+1,458% +$249K ﹤0.01% 5324
2023
Q1 		$16.7K Sell
1,449
-8,127
-85% -$106K ﹤0.01% 7220
2022
Q4 		$111K Buy
9,576
+8,530
+815% +$98.7K ﹤0.01% 6004
2022
Q3 		$13K Buy
1,046
+16
+2% +$183 ﹤0.01% 8017
2022
Q2 		$7K Sell
1,030
-9,142
-90% -$63K ﹤0.01% 8471
2022
Q1 		$98K Buy
10,172
+9,760
+2,369% +$83.1K ﹤0.01% 5933
2021
Q4 		$5K Buy
412
+387
+1,548% +$5.44K ﹤0.01% 9387
2021
Q3 		$0 Buy
+25
New +$443 ﹤0.01% 9653
2021
Q2 		– Sell
-3,278
Closed -$51K – 9463
2021
Q1 		$51K Sell
3,278
-6,682
-67% -$129K ﹤0.01% 6516
2020
Q4 		$209K Buy
+9,960
New +$197K ﹤0.01% 5217

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group's DYN Position: Q2 2026 in Review

UBS Group increased its Dyne Therapeutics (DYN) stake by 16% in Q2 2026, buying an estimated $1.17M and bringing the position to 443,284 shares worth $9.85M. The position accounts for ﹤0.01% of the portfolio, ranked #3468.

UBS Group first reported a position in DYN in Q4 2020 and has held it in 22 quarters since. The position peaked at $22.5M in Q3 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • UBS Group held 443,284 shares of Dyne Therapeutics worth $9.85M as of Q2 2026.
  • UBS Group bought 62,723 Dyne Therapeutics shares in Q2 2026, an estimated $1.17M.
  • Dyne Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3468 holding.
  • UBS Group first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • UBS Group's Dyne Therapeutics position peaked at $22.5M in Q3 2024.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.